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Abstract: 
Cytochromes P450 are highly versatile biocatalysts due to their ability to introduce molecular oxygen 
into a non-activated C-H bond. In this work, nine P450 enzymes from Sorangium cellulosum So ce56 
were investigated concerning their substrate range and catalytic biodiversity. Hence, terpenes, 
terpenoids, carotenoid-derived aroma compounds, aromatic compounds and drugs were tested as 
potential substrates for CYP109C1, CYP109C2, CYP109D1, CYP260A1, CYP260B1, CYP264A1, 
CYP264B1, CYP267A1 and CYP267B1. Those systems showing a highly selective product pattern 
towards a single product were chosen to be scaled up in an E. coli based whole-cell system for the 
formation of sufficient amounts of products for structure elucidation via NMR spectroscopy. During 
these studies, tricyclic psychotherapeutic drugs, ionones, damascones as well as terpenes and 
terpenoids were identified as novel substrates for some the tested P450s and several of their 
products were characterized. For the carotenoid-derived aroma compounds and sesquiterpenes, 
novel products such as the hydoxylated derivatives of allyl-ionones and δ-damascone or the 
oxyfunctionalized derivatives of zerumbone and cedrenol were identified, whereas the conversion of 
tricyclic drugs led to the same metabolites as those produced by human P450s. These results 
demonstrate the high diversity towards the substrate range and reaction types performed by the 
myxobacterial P450s and, therefore, their potential biotechnological applications. 
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Zusammenfassung: 
Cytochrome P450 sind vielseitig einsetzbare Biokatalysatoren, da sie molekularen Sauerstoff in eine 
nicht aktivierte C-H Bindung einbauen können. In dieser Arbeit wurden neun P450 Enzyme von 
Sorangium cellulosum So ce56 bezüglich ihrer Substratspezifität und katalytischen Vielfalt 
untersucht. Aus diesem Grund wurden Terpene, Terpenoide, Norisoprenoide, aromatische Moleküle 
und pharmazeutische Wirkstoffe als potentielle Substrate für CYP109C1, CYP109C2, CYP109D1, 
CYP260A1, CYP260B1, CYP264A1, CYP264B1, CYP267A1 und CYP267B1 untersucht. Die Substrate, 
deren Produktmuster eine hohe Selektivität für ein einzelnes Hauptprodukt zeigen, wurden mit Hilfe 
eines Ganzzellsystems im großen Maßstab umgesetzt, um eine ausreichende Menge an Produkt für 
die NMR Analyse zu erhalten. Dabei wurden trizyklische Psychopharmaka, Ionone, Damascone sowie 
verschiedene Terpene und Terpenoide als neue Substrate für einige dieser P450s identifiziert. Für die 
Norisoprenoide und Sesquiterpene wurden die hydroxylierten δ-Damascon- und Allyl-ionon-Derivate 
sowie die oxidierten Zerumbon- und Cedrenolderivative als neue Produkte identifiziert. Im Gegensatz 
dazu wurden die trizyklischen Wirkstoffe zu den gleichen Metaboliten umgesetzt, die schon von den 
humanen P450s bekannt sind. Diese Ergebnisse verdeutlichen die potentiellen biotechnologischen 
Anwendungsgebiete der myxobakteriellen P450s aufgrund ihres großen Substratspektrums sowie 
ihrer katalytischen Vielfältigkeit. 
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1. Introduction 
1.1 Cytochromes P450 
1.1.1 Background and nomenclature 
In 1958, Garfinkel and Klingenberg discovered red pigments out of rat and pig livers, respectively 
(Garfinkel 1958; Klingenberg 1958). These pigments were named cytochrome P450 (P450) by 
Omura and Sato in 1962 due to their characteristic absorption maximum at 450 nm in the 
reduced and carbon monoxide bound form. In contrast, other hemo-proteins show a typical 
absorption maximum at 420 nm (Omura and Sato 1962). P450s contain a Fe3+-ion that is 
coordinated by a protoporphyrin IX as well as water and cysteine as axial ligands, whereby 
cysteine causes the specific absorption maximum at 450 nm. In 1963, Estabrook, Cooper and 
Rosenthal discovered their enzymatic activity in the metabolism of steroids (Estabrook et al. 
1963). One year later, Omura and Sato published the detailed spectroscopic properties as well as 
the location of P450s in mitochondria of adrenal cortex (Omura and Sato 1964a; Omura and Sato 
1964b). The electron transfer proteins adrenodoxin reductase and adrenodoxin as well as the 
reconstitution of a NADPH-dependent steroid 11β-hydroxylase activity of a P450 were 
discovered in 1966 (Omura et al. 1966). The first bacterial P450 was found in Rhizobium 
bacteroids and, in contrast to the mammalian P450s, the Rhizobium P450 was soluble (Appleby 
1967). Since that time, P450s were discovered in all domains of life and over 21,000 different 
P450s (http://drnelson.uthsc.edu/CytochromeP450.html) were already identified (Nelson 2011). 
They were found in mammalians, bacteria, archaea, fungi, plants and in 2009 the first viral P450 
was discovered (Lamb et al. 2009). To classify this variety of P450s, a systematic nomenclature 
was introduced in 1987 (Nebert et al. 1987). The abbreviation CYP stands for cytochrome P450 
while the first number gives the membership of the family (over 40% identity of the amino acid 
sequence). The first letter indicates the subfamily (over 55% identity of the amino acid sequence) 
and the last number represents the specific isoenzyme. The following figure shows the example 
of CYP260A1 from Sorangium cellulosum So ce56. 
 
Figure 1: Nomenclature of the P450s exemplified by CYP260A1 from Sorangium cellulosum So ce56. 
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1.1.2 Functions and reactions 
P450s belong to the class of oxidoreductases, enzymes that catalyze the electron transfer from 
one molecule to another one. P450s are monooxygenases and catalyze the activation of 
molecular oxygen, whereby one oxygen atom can insert into a non-activated C-H bond, whereas 
the other oxygen atom is reduced to water. The required electrons are provided by a cofactor 
such as NAD(P)H and delivered to the P450 by electron transfer proteins. Thus, the 
oxyfunctionalization of organic compounds is performed by P450s as shown in Figure 2. 
The physiological roles of many P450s, especially for those found in bacteria, fungi and plants, 
are not discovered yet. In contrast, the physiological function of many human P450s has been 
identified, albeit there are still some orphan P450s (Guengerich and Cheng 2011). Human P450s 
are mainly involved in the biosynthesis of steroids, prostaglandins, vitamin D3 or fatty acids as 
well as in the metabolism of drugs and other xenobiotics (Bernhardt 2006). The steroid hormone 
biosynthesis takes place in the adrenal cortex, whereby 6 P450s are capable of the formation of 
mineralocorticoids, glucocorticoids and sexual hormones. In contrast, the clearance of drugs is 
mainly performed in the liver and about 75% of all drugs are metabolized by P450s. Thereby, 
about 90% of the P450 catalyzed reactions can be accounted to CYP1A2, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4. The CYP3A enzymes play the most important role by performing about 
45% of all P450 catalyzed reactions (Rendic and Guengerich 2014). In general, the liver P450s and 
steroidogenic P450s belong to the best characterized human P450s since steroidal P450s were 
discovered first and the characterization of drug metabolizing P450s is required by the 
pharmaceutical industry. 
 
Figure 2: General reaction catalyzed by P450s 
There are several different reaction types performed by P450s and still new types of reactions 
are being discovered (Coelho et al. 2013; Ren et al. 2015). The most common reactions catalyzed 
by these P450s are hydroxylation, epoxidation, N-, O- and S-dealkylation, the oxidation of 
heteroatoms as well as the oxidation of olefins and acetylenes. Besides these typical examples, 
there are several uncommon reactions catalyzed such as reduction, desaturation, oxidative ester 
cleavage, ring expansion, ring formation, aldehyde scissions, dehydration, one electron oxidation, 
coupling reactions, isomerization and several more (Guengerich 2001). These various types of 
reactions show the high diversity and importance of the P450s for the production of structurally 
diverse compounds. Also the substrate range differs for the various P450s. For example, the liver 
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P450 CYP3A4 is capable of the metabolism of about 27% of all drugs indicating its very broad 
substrate range (Rendic and Guengerich 2014). In contrast, other P450s like the steroid 
hydroxylase family CYP11B are very selective concerning their substrate range (Schiffer et al. 
2015a). This substrate diversity is caused by the substrate recognition sites (see Figure 6) and 
turns the identification of novel or natural substrates to a challenging process. 
1.1.3 Catalytic cycle  
The catalytic cycle of P450s was first postulated in 1968 and several improvements were done 
since that time (Gunsalus et al. 1975). The analysis of intermediates involved in this cycle is 
challenging caused by some instable intermediates whose presence is short-time. Nevertheless, 
spectroscopic and crystallographic methods enabled the elucidation of several intermediates and 
it is postulated that there are eight intermediates involved in the catalytic reaction of P450s as 
shown in Figure 3 (Denisov et al. 2005). The cycle begins with water as sixth distal ligand to 
stabilize the low spin state of the ferric Fe3+ (1). Then the water is displaced by the substrate and 
the five coordinated heme iron shifts to the high-spin state (2). This spin shift causes a change in 
the redox potential and Fe3+ can be reduced to Fe2+ by the uptake of an electron (3). Molecular 
oxygen and carbon monoxide are strong ligands for the Fe2+ resulting either in the CO-bound 
form or in the case of the catalytic cycle in the oxy-ferrous state (4). This state is further reduced 
to a ferric peroxoanion (5a) leading to the ferric hydroperoxo intermediate (compound 0; 5b) 
after the uptake of a proton. This intermediate can release a water molecule after the 
acceptance of a further proton forming an iron-oxo state (compound I; 6). Compound I is highly 
reactive and can, therefore, interact with the substrate to form the oxygenated product. The 
exact mechanism of the hydroxylation step is not yet clarified, however, a two-state reactivity 
mechanism (TSR), in which compound I abstracts a hydrogen followed by a rebound of the alkyl 
radical, is proposed (Shaik et al. 2002). The newly formed product is then released and the cycle 
can restart. Besides the “typical” cycle, there are some uncoupling pathways like the 
autooxidation shunt, peroxide shunt or oxidase shunt (grey dashed arrows). These shunts 
decrease the catalytic efficiency by the unproductive consumption of NAD(P)H (Meunier et al. 
2004). 
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Figure 3: Catalytic cycle of the P450 mechanism. Figure was adopted from (Kiss et al. 2015). 
The changes of the spin- and oxidation-state can be investigated by spectroscopic 
measurements. The carbon monoxide difference spectroscopy leads to the determination of the 
protein concentration (Omura and Sato 1964a; Omura and Sato 1964b). Additionally, binding 
studies of either substrates or inhibitors can be performed by studying the spin state shift of the 
heme iron. The high spin state is represented by an absorption maximum at 390-394 nm, 
whereas a maximum at 415-417 nm represents the low spin state. By adding a substrate to the 
protein solution, water is displaced as sixth ligand and the equilibrium shifts to the high spin 
state. The result is a typical type-I spectrum with a maximum at about 390-394 nm and a 
minimum at 415-417 nm. By adding an inhibitor, a typical type-II spectrum is obtained with a 
maximum at about 415-417 nm and a minimum at 390-394 nm (Meunier et al. 2004; Luthra et al. 
2011). 
1.1.4 Electron transfer partners 
As shown in the cycle before, P450s need electrons from an external source to catalyze the 
oxyfunctionalization. The most common provider for electrons is NAD(P)H, however P450s are 
not able to interact with this cofactor in a direct way. As a result, additional electron transfer 
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proteins are required to enable the electron transfer between NAD(P)H and the P450. There are 
several classes of electron transport chains, whereby the mitochondrial and microsomal systems 
are the most prominent ones. The mitochondrial system in mammalians consists of a membrane 
anchored reductase possessing FAD as prosthetic group, and a soluble ferredoxin containing an 
iron sulfur cluster. On the other hand, the mammalian microsomal system consists of a single 
electron transport protein called NADPH cytochrome P450 reductase (CPR). The CPR is also 
membrane anchored and possesses both, a FAD and a FMN domain to transfer the electrons. The 
FAD domain interacts thereby as electron acceptor for NAD(P)H, whereas the FMN domain 
delivers electrons to the P450 (Wang et al. 1997). These two systems do not only exist in 
mammals but also in bacteria with the difference that all redox partners as well as the P450 are 
soluble in bacterial systems. There are several other classes of electron transfer systems known 
for the bacterial system including fusion proteins having the P450 and reductase components 
fused into a single polypeptide chain. CYP102A1 (P450BM3) from Bacillus megaterium is the most 
prominent example of such a self-sufficient P450. Due to this specific property, P450BM3 can 
directly interact with NAD(P)H and deliver the electrons to the iron of the heme domain 
(Hannemann et al. 2007). 
 
Figure 4: Class 1 electron transfer system of bacteria. The ferredoxin reductase (FdR), ferredoxin (Fdx) 
and P450 are soluble. The electrons are provided by the cofactor NAD(P)H, transferred to FdR and 
shuttled to the P450 by the ferredoxin. 
The electron transfer proteins from Sorangium cellulosum So ce56 are analogous to the soluble 
class 1 system (see Figure 4). Two ferredoxin reductase genes and eight ferredoxin genes were 
identified in So ce56, whereby Fdr_A, Fdr_B, Fdx2 and Fdx8 were demonstrated as efficient 
electron transfer proteins for CYP260A1 (Ewen et al. 2009). Nevertheless, the application of 
autologous redox partners is not required, since several P450s are known for their interaction 
with heterologous electron transfer proteins (Hannemann et al. 2007). This can be explained by 
the highly conserved interaction domains of P450s as well as those of their redox partners 
(Hlavica 2015). Thereby, the application of heterologous redox partners is of interest for P450s 
whose natural redox partners are still not known. Additionally, replacing the redox partners by 
heterologous electron transfer proteins can lead to an increased product yield which is of 
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interest for biotechnological applications (Ringle et al. 2013; Brixius-Anderko et al. 2015; Kern et 
al. 2015). This might be explained by the higher activity of the heterologous redox partners, their 
solubility or their increased expression level. There is also a report about the altered reaction 
type after applying a fused or a non-fused hybrid redox system, respectively (Zhang et al. 2014). 
Hence, the choice of redox partners is a significant parameter regarding the efficiency of a 
catalytic system. 
1.1.5 Structure of P450s 
Although having an amino acid sequence identity frequently lower than 20%, P450s show a 
similar structural fold (Graham and Peterson 1999). In general, they usually possess 4 β-sheets 
and 12 α-helices (A-L) (see Figure 5). Thereby, the core is highly conserved showing a four helix 
bundle composed by the helices D, L, I and the antiparallel helix E, the helices J and K as well as 
two β-sheets and a coil called “meander” (Werck-Reichhart and Feyereisen 2000). The prosthetic 
heme group is confined between the distal I helix and proximal L helix and bound to the adjacent 
Cys-heme-ligand loop containing the P450 signature amino acid sequence FxxGx(H/R)xCxG. The 
cysteine residue as fifth ligand of the heme iron is conserved in all P450s and responsible for the 
characteristic 450 nm Soret band. The I-helix forms a wall of the heme pocket and contains the 
signature amino acid sequence (A/G)-Gx(E/D)T. Moreover, the highly conserved threonine is 
positioned in the active site and seems to be involved in the catalysis (Denisov et al. 2005). 
 
Figure 5: Topology diagram showing the secondary structure of CYP102. Blue boxes represent the α-
helices and the cream arrows represent the β-sheets. Figure was adopted from (Werck-Reichhart and 
Feyereisen 2000). 
Despite their structural similarity, the substrate range and selectivity differ for all P450s. There 
are six substrate recognition sites (SRS) capable of the predetermination of the substrate 
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specifity (see Figure 6). The SRSs consist of the B’ helix (SRS1), parts of the F, G and I helices 
(SRS2, SRS3 and SRS4), the β4 hairpin (SRS5) and the K helix β2 connecting site (SRS6). The SRSs 
are more flexible protein regions and, therefore, involved in the substrate recognition and 
orientation (Gotoh 1992). 
 
Figure 6: Model of the tertiary structure of a P450 monooxygenase. The heme is colored in orange, the 
substrate recognition sites (1-6) are colored in red and the heme coordinating helices I and L are shown 
in green. Figure was adopted from (Urlacher and Eiben 2006). 
 
1.2 Bacterial P450s 
1.2.1 General aspects 
The first bacterial P450 was identified in Bradyrhizobium japonicum in 1967 but its natural 
function was not elucidated (Appleby 1967). P450cam (or CYP101) from Pseudomonas putida 
was described a little bit later and catalyzes the oxidation of camphor and was, therefore, the 
first bacterial P450 with a known functionality (Katagiri et al. 1968). This enzyme was also the 
first P450 for which the crystal structure was obtained (Poulos et al. 1985). In the last two 
decades, various sequencing projects revealed the appearance of P450 genes in diverse bacteria. 
The identification of the strictly conserved heme-binding domain signature is used for that 
purpose (Nelson 1999). So far, over 1,000 bacterial P450s were already identified (Kelly and Kelly 
2013). For example, Streptomyces avermitilis has 33 P450 genes, Sorangium cellulosum So ce56 
21, whereas Escherichia coli has none P450 genes (Kelly et al. 2003; Khatri et al. 2010b). The 
absence of P450s proves that these enzymes are not needed in all organisms, however, P450s 
seem to be essential for organisms with a higher complexity (Kelly et al. 2003). 
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The physiological role of many bacterial P450s is not identified yet; however, their biodiversity is 
often bound up with using different carbon sources for growth (Kelly and Kelly 2013). The 
bacterial P450 177A1 permits growth on hexahydro-1,3.5-trinitro-1,3.5-triazin (RDX) and 
subsequent phytoremediation (Rylott et al. 2006). Furthermore, Candida tropicalis is able to 
grow on oil, whereby P450s are involved in the metabolism of this carbon source (Lebeault et al. 
1971). Besides their functions as carbon source metabolizer, there are several more natural 
functions elucidated. They are involved in the catabolism of camphor, fatty acids or cholesterol 
as well as in the biosynthesis of antifungal, antibacterial or anti-tumor agents such as nystatin, 
novobiocin or epothilone (Kelly and Kelly 2013). Nevertheless, the determination of their natural 
function is a challenging task even if the CYPome is known. Operons can give first clues for their 
enzymatic activities as well as experiments such as gene knock-outs or conversions of specific 
substrates with purified enzymes. However, organisms, where P450s are not associated with an 
operon or lacking of information about the metabolomics hinder the elucidation of the 
physiological roles of these P450s (Kelly and Kelly 2013). 
Nevertheless, their unique catalytic activities towards structurally diverse compounds as well as 
their valuable properties, like high selectivity or expression rates turn these P450s in a promising 
tool for the oxyfunctionalization of organic compounds. Additionally, their solubility facilitates 
the handling of the microbial P450s compared with mammalian P450s (Bernhardt 2006). The 
solubility is not only accounting for the P450s but also for their natural redox partners influencing 
the catalyzed reactions in a significant manner (Ringle et al. 2013; Brixius-Anderko et al. 2015). 
Since there are bacterial P450s containing a fused electron transfer domain, the utilization of 
external redox partners is no longer required in these systems (Hannemann et al. 2007). The best 
characterized bacterial fusion P450 is CYP102A1 (P450BM3) from Bacillus megaterium. It was 
discovered in 1987 and since that time the substrate free as well as several substrate-bound 
crystal structures were published. Besides the crystallographic characterization, it is also one of 
the best studied P450s towards protein engineering (Whitehouse et al. 2012). P450BM3 and its 
mutants are capable of the conversion of structurally diverse classes of substrates ranging from 
fatty acids (Munro et al. 2002), over terpenes (Whitehouse et al. 2012) to drugs (Ren et al. 2015). 
Thereby, several reaction types like hydroxylation, epoxidation, dealkylation (Jung et al. 2011) as 
well as some novel reactions such as the formation of a protected imine from an amine (Ren et 
al. 2015) or the cyclopropantion by the P411BM3 variant (Coelho et al. 2013) were observed. 
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1.2.2 Myxobacterial P450s from Sorangium cellulosum So ce56 
Sorangium cellulosum So ce56 belongs to the group of myxobacteria, a group of gram-negative, 
unicellular bacteria with rod-shaped vegetative cells. Their specific characteristics are the gliding 
movement and the formation of fruiting bodies under starvation conditions (Shimkets et al. 
2006). Myxobacteria are important producers of novel classes of secondary metabolites, like the 
anti-tumor agents epothilone A and B produced by the strain So ce90 (Gerth et al. 1996). Such 
metabolites may be used as drugs or might serve as lead structures for the development of novel 
drugs and, hence, attract the attention of the pharmaceutical industry (Newman and Cragg 
2012). The involvement of P450s in the production of these complex molecules is known as 
shown for EpoK and its epoxidase activity towards epothilones C and D (Julien and Shah 2002). As 
a result, the investigation of myxobacteria as well as their P450s is of particular interest. The 
strain So ce56 has one of the largest genomes and was sequenced in 2007. Several polyketide 
synthases (PKS) and nonribosomal polypeptide synthetases (NPRS) were identified giving first 
insights into the secondary metabolism of this strain, whereby chivosazol, etnangien, myxochelin 
and flaviolin were characterized as products. Furthermore, there are additional PKS and NRPS 
domains whose products are not known as well as domains which are potentially involved in the 
carotenoid and terpenoid biosynthesis. Taken together, 17 unique loci involved in the secondary 
metabolism were identified (Schneiker et al. 2007). 
Our laboratory investigated the CYPome of So ce56 and 21 P450 genes were identified, cloned 
and successfully expressed and purified (Khatri et al. 2010b). Moreover, the ferredoxins Fdx2 and 
Fdx8 as well as the reductases FdR_A and FdR_B were identified, expressed, purified and tested 
for their ability to transfer electrons to the myxobacterial P450s revealing their natural 
functionality (Ewen et al. 2009; Khatri et al. 2010b). Besides their natural redox partners, the 
non-physiological electron transfer partners adrenodoxin reductase (AdR) and adrenodoxin (Adx) 
as well as the truncated form Adx4-108 from Bos taurus are also known for their efficient electron 
transfer (Khatri et al. 2010a). However, the physiological roles of these P450s are not known yet 
and also about potential substrates only little is known. Several substrate classes were already 
tested and fatty acids (Khatri et al. 2010b), carotenoid-derived aroma compounds (Khatri et al. 
2010a; Ly et al. 2012), terpenes, terpenoids (Ewen et al. 2009; Schifrin et al. 2015) and steroids 
(Khatri et al. 2015) were found to act as substrates for some of the P450s. 
To determine the reaction type and selectivity of the catalyzed reactions, the product(s) need to 
be analyzed. The most common techniques to elucidate the structures are mass spectrometry 
with database comparison of the fragment pattern, nuclear magnetic resonance spectroscopy or 
the comparison with an authentic standard. If standards are not available, MS or NMR analyses 
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are necessary for product identification. During MS analyses, the compounds are fragmented and 
the fragment patterns are compared with a database. Hence, an efficient database is required 
since it is very challenging to characterize novel compounds solely by their specific fragments. 
For that reason, NMR spectroscopy is preferred to elucidate the structure of novel compounds; 
however, higher amounts of products are necessary for NMR analysis. Sufficient amounts of 
products can be either obtained by scaling up the in vitro reaction or the application of a whole-
cell system. Since the in vitro reactions require high amounts of purified enzymes (P450 and 
redox partners) and the expensive cofactor NADPH, the application of a scaled up in vitro system 
is limited. To overcome this problem, an E. coli based whole-cell system was established for some 
of the myxobacterial P450s (Ringle et al. 2013). 
1.3 P450s as biocatalysts for biotechnological applications 
The regio-, and stereoselective oxyfunctionalization of a non-activated C-H bond is a challenging 
task in the organic chemistry. In contrast, P450s are known for their highly selective catalytic 
activity under mild conditions. The lack of organic solvents and the absence of toxic chemicals 
like heavy metals is especially beneficial (Koeller and Wong 2001; Roiban and Reetz 2015). 
Furthermore, their diverse reaction types and broad substrate range is advantageous for 
biotechnological applications. However, the low activity, the utilization of redox partners, the 
requirement of the expensive cofactor NAD(P)H and uncoupling reactions limit their possible 
range of applications. Many of these limitations can be overcome by using techniques like 
protein engineering, optimization of the redox chain or the application of a cofactor regenerating 
system (Julsing et al. 2008; Bernhardt and Urlacher 2014). The increasing number of P450s with 
novel biotechnological properties, efforts in protein engineering techniques and improvements 
in whole-cell biocatalysis are helpful to turn P450s into a valuable tool for the green chemistry 
(Julsing et al. 2008). Besides employing them as single catalysts, there are also examples of 
combining P450s with synthetic chemistry in chemo-enzymatic approaches or the utilization of 
multiple enzymes in a cascade reaction (Rentmeister et al. 2009; Schulz et al. 2015). 
P450s can be applied as biocatalysts for the production of fine chemicals and pharmaceutically 
active compounds (Kumar 2010). Terpenes and their oxygenated derivatives (terpenoids) 
represent an interesting group of fine chemicals that is of importance for the flavor and 
fragrance industry (Kraft et al. 2000). For example, P450BM3 mutants are involved in the 
regioselective epoxidation of α-pinene and the optimization of the production process led to the 
formation of 1 g/l after 4h (Urlacher and Girhard 2012). Another interesting compound is (+)-
nootkatone, a grapefruit flavour, formed by the oxidation of (+)-valencene. Urlacher and 
coworkers firstly used CYP109B1 from Bacillus subtilis to form the desired product nootkatone 
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out of valencene in a direct way. The utilization of a two liquid phase system to increase the yield 
led to a production of 120 mg/l with cis- and trans-nootkatol as side-products. However, the 
formation of nootkatol as side-product decreases the yield of nootkatone (Girhard et al. 2009). 
To avoid these side-products, a cascade reaction consisting of a P450 hydroxylating valencene to 
nootkatol and an alcohol dehydrogenase oxidizing the alcohol in situ to the desired nootkatone 
was used. This multi-enzyme approach led to a yield of over 300 mg/l (Schulz et al. 2015). 
Metabolic engineering is another method to obtain terpenoids. Such an approach uses several 
enzymes representing the metabolic pathway to form the precursor which is then further 
oxygenated. For example, diverse enzymes were expressed in E. coli to produce the terpene 
precursor GPP followed by a terpene synthase forming limonene. The additional expression of a 
P450 (CYP153 from mycobacterium HXN 1500) led to the formation of perillylic alcohol out of 
simple sugars with yields up to 100 mg/l (Alonso-Gutierrez et al. 2013). Besides the formation of 
terpenoids, there are several other classes of substrates which can be used for the production of 
fine chemicals such as fatty acids or alkanes (Picataggio et al. 1992; Liu et al. 2004). 
The production of pharmaceutical and medicinal compounds is also of considerable interest, 
since P450s are involved in the metabolism of drugs. Drug metabolites might have adverse 
effects and a possible toxicity must be determined. Hence, the Food and Drug administration as 
well as the European Medicines agency presented their guidelines concerning the safety testing 
of drug metabolites. Drug metabolites formed at greater than 10% of the parent drug systemic 
exposure at steady state or total drug-related exposure need to be tested in toxicological studies 
(FDA 2008; ICH 2009). Moreover, these metabolites might be used as authentic standards for 
analytical purposes or also used as drugs or lead structure to develop novel pharmaceutical 
compounds. The production of these metabolites can be performed by either mammalian or 
bacterial P450s, whereby engineering of the P450s is often necessary. Many bacterial P450s need 
to be engineered to enable the biotransformation of the non-natural substrates (Ren et al. 2015). 
In contrast, mammalian P450s are capable of the desired conversion but often show a low 
activity or the formation of multiple products and, hence, require improvements by protein 
engineering, too. However, bacterial P450s seem to be more suitable due to their high turnover 
rates, stability and expression levels (Urlacher et al. 2004; Julsing et al. 2008).  
P450s are also capable of the oxyfunctionalization of structurally diverse compounds in the 
secondary metabolism of plants and bacteria (Podust and Sherman 2012). Between 1981 and 
2010, 1334 drugs were approved of which 64 are natural products, 202 have a biological origin, 
299 are derivatives of natural products and 323 are synthetics mimicking a natural product 
(Newman and Cragg 2012). This distribution shows the influence of secondary metabolites and 
Introduction 
14 
 
myxobacteria are known as top producers of such biologically active compounds (Reichenbach 
and Hofle 1993). Epothilones are produced by the myxobacterium So ce90 and these compounds 
attract the attention of the pharmaceutical industry due to their anti-tumor activity (Gerth et al. 
1996). There are already examples of the biotechnological application of P450s in the 
biosynthesis of secondary metabolites such as the anticancer drug taxol or artemisinin, an agent 
for the treatment of malaria (Ajikumar et al. 2010; Paddon et al. 2013). Additionally, in the 
biosynthetic pathway for the production of the anti-cholesterol drug pravastatin, P450sca from 
streptomyces carbophilus is used (Matsuoka et al. 1989). These applications of P450s for the 
formation of biologically active secondary metabolites show the significance of these enzymes 
for the regio-, and stereoselective oxyfunctionalization of complex molecules. 
Due to their involvement in the steroid hormone biosynthesis, P450s are also employed in the 
biotechnological production of steroids and their derivatives. An article about the screening of 
bacterial P450s for their selective hydroxylase activity towards testosterone was published in 
2006 and shows the activity of such P450s for the highly selective formation of a single main 
product (Agematu et al. 2006). Two reviews about the microbial biotransformation of steroidal 
compounds were published in 2012, showing the significance of these enzymes towards steroid 
conversion (Bhatti and Khera 2012; Donova and Egorova 2012). However, microbial conversions 
employing whole organisms lack the information about the specific enzyme that is capable of the 
desired reaction. Furthermore, the probability of a multi-hydroxylation reaction caused by the 
involvement of more than one enzyme is much higher. But this screening approach is the fastest 
way to identify new product patterns. Thereby, novel hydroxylase activities are of high interest, 
since the introduction of a hydroxyl-group alters the chemo-physical properties of the molecule. 
The influence of such a functional group can be shown for steroids hydroxylated in position 11 
and their resulting anti-inflammatory effect (Ruhmann and Berliner 1967). A novel hydroxylase 
activity was recently found for a P450 from So ce56, where CYP260A1 acts as 1α-hydroxylase for 
C19 steroids, however, the functions of these new compounds were not investigated yet (Khatri 
et al. 2015). 
Taken together, P450s are valuable tools in the biotechnological production of fine chemicals and 
biologically active compounds, whereby investigations of novel or improved activities are a 
promising field of research. 
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1.4 Aims and scope 
The aim of this work is the investigation of myxobacterial P450s from Sorangium cellulosom So 
ce56 towards their substrate range and biodiversity. Their physiological roles and, hence, their 
substrate range are not identified yet. About potential substrates and performed reactions only 
little is known and, as a result, several classes of substrates should be tested for their ability to 
act as a substrate for these P450s. For that purpose, terpenes, terpenoids, carotenoid-derived 
aroma compounds, small aromatic compounds and diverse drugs, which are known to serve as 
substrates for other P450s, were chosen. Initially, all substrates should be tested in a 
reconstituted in vitro system with the P450s CYP109C1, CYP109C2, CYP109D1, CYP260A1, 
CYP260B1, CYP264A1, CYP264B1, CYP267A1 and CYP267B1. To perform such in vitro reactions, 
the expression and purification of the corresponding P450s as well as the redox partners, 
adrenodoxin and adrenodoxin reductase, is necessary. Moreover, efficient extraction methods 
need to be established for each substrate class to recover the substrates as well as their 
corresponding products. The conversions should then be analyzed by HPLC-DAD or GC-MS 
depending on the physical properties of the analytes such as UV-absorption or volatility. For this 
purpose, substrate class dependent HPLC- and GC-methods are required.  
Those systems showing a selective product pattern during the in vitro conversions should be 
further analyzed to elucidate the structures of the products. For that reason, the reactions need 
to be scaled up by utilizing an E. coli based whole-cell system harboring the corresponding P450 
as well as the redox partners Fpr and Adx. Using such an approach, sufficient amounts of 
products of at least 5 mg should be obtained to enable the structure identification via NMR-
spectroscopy. To fulfill that requirement, the whole-cell systems need optimizations towards the 
yields by testing diverse conversion conditions like performing the reaction with growing cells or 
resting cells in buffer. Furthermore, the utilization of additives such as cell permeabilizing agents 
like EDTA is often necessary to reach the desired productivity. Before the products can be 
characterized, individual purification strategies based on either preparative HPLC or column 
chromatography with silica gel need to be developed for each class of compounds. The purified 
products should then be characterized by HPLC-DAD and GC-MS as well as by several NMR 
techniques such as 1H, 13C, HSQC, HMBC, COSY and NOESY to identify the reaction types 
performed by these P450s. Furthermore, the corresponding structures should give insights into 
the regio- and stereoselectivity of the catalyzed reactions. 
The elucidated products should then be compared with the products formed by other P450s to 
check if the myxobacterial P450s are capable of some unique reaction types or showing certain 
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regio- and stereoselectivities. Moreover, the substrate range and the biocatalytic activities of the 
myxobacterial P450s should lead to some speculations about their potential natural functions. 
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2. Scientific articles 
The results of this work were published in the articles listed below: 
 
2.1 Conversions of tricyclic antidepressants and antipsychotics with selected P450s from 
Sorangium cellulosum So ce56 
Martin Litzenburger, Fredy Kern, Yogan Khatri, and Rita Bernhardt 
 
2.2 New Sesquiterpene Oxidations with CYP260A1 and CYP264B1 from Sorangium cellulosum 
So ce56 
Alexander Schifrin, Martin Litzenburger, Michael Ringle, Thuy TB Ly, and Rita Bernhardt 
 
2.3 Selective oxidation of carotenoid-derived aroma compounds by CYP260B1 and CYP267B1 
from Sorangium cellulosum So ce56 
Martin Litzenburger and Rita Bernhardt 
 
2.4 CYP267A1 and CYP267B1 from Sorangium cellulosum So ce56 are highly versatile drug 
metabolizers (submitted to Drug metabolism and Disposition) 
Fredy Kern, Yogan Khatri, Martin Litzenburger, and Rita Bernhardt 
Litzenburger et al. (2015) 
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Sorangium cellulosum So ce56 
Martin Litzenburger, Fredy Kern, Yogan Khatri, and Rita Bernhardt 
 
Drug Metabolism and Disposition, 2015 Mar, 43(3), 392-399 
doi: 10.1124/dmd.114.061937 
Reprinted with permission of the American Society for Pharmacology and Experimental 
Therapeutics. All rights reserved. 
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2.2 New Sesquiterpene Oxidations with CYP260A1 and CYP264B1 from Sorangium cellulosum So 
ce56 
Alexander Schifrin, Martin Litzenburger, Michael Ringle, Thuy TB Ly, and Rita Bernhardt 
 
ChemBioChem, December 14, 2015, Volume 16, Issue 18, pages 2624–2632 
doi: 10.1002/cbic.201500417 
Reprinted with permissions of Wiley-VCH Verlag GmbH&Co. KGaA. 
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Applied Microbiology and Biotechnology [Epub ahead of print] 
doi: 10.1007/s00253-015-7269-7 
Reprinted with the permission of Springer Science and Business Media. 
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3 Discussion and Conclusions 
The aim of this work was the determination of novel substrates for P450s from Sorangium 
cellulosum So ce56 as well as the elucidation of their corresponding products. Hence, several 
classes of compounds were chosen to test their ability to serve as substrate. The investigation of 
substrates as well as their products is essential to obtain insights in the substrate range and 
selectivity of the P450s. In addition, knowledge about substrates is necessary to investigate these 
P450s in more detail, like for the crystallization in a substrate-bound form, determination of the 
activity or to test the influence of inhibitors. For that reason, the investigation of substrates as 
well as their corresponding products is of interest to further characterize these promising P450s. 
Carotenoid-derived aroma compounds, terpenes, terpenoids, small aromatic compounds as well 
as drugs are known to serve as substrates for other P450s and, therefore, seem to be a good 
starting point for finding novel substrates of orphan P450s. Oxygenated products of these 
compounds are of interest for different kind of applications. Terpenoids may act as flavors and 
fragrances as shown for the conversion of valencene to the grapefruit flavor nootkatone (Schulz 
et al. 2015) or used as building blocks for the synthesis of chemically and pharmaceutically 
important compounds (Wang et al. 2005). Carotenoid-derived aroma compounds are already 
applied as material in perfumery and their oxyfunctionalization alters the odor properties as well 
as the odor threshold as shown for the 3-hydroxy derivatives of α-ionone and their tobacco-like 
odor (Yamazaki et al. 1988). Furthermore, functionalized carotenoid-derived aroma compounds 
can also be used as precursors for some synthetic routes (Brenna et al. 2002). Drugs are 
predominantly metabolized by liver P450s and their respective metabolites need several safety 
tests before they can be administered and, as a result, alternative ways for their production are 
requested by the pharmaceutical industry. A further application for all these products is their 
utilization as authentic standard to simplify the product characterization for other P450-based 
conversions. 
3.1 Carotenoid-derived aroma compounds as substrates 
Many carotenoid-derived aroma compounds (apocarotenoids, norisoprenoids or norterpenoids) 
used in these studies belong to the most widespread class of C13 norisoprnoids such as ionones 
(see Figure 7 B [R=H]) and damascones (see Figure 7 A). Synthetic methyl-substituted ionones 
like n-methyl-α-ionone (see Figure 7 B [R=Me]) and isomethyl-α-ionone belong to the C14 
norisoprenoids and are of high importance for the perfumery. On the other side, α-irone is a 
naturally occurring C14 norisoprenoid, however, its higher price limits the application in 
perfumery. Additionally, allyl-α-ionone (a synthetic C16 norisoprenoid, see Figure 7 B [R=allyl]) 
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was tested in our studies, a compound of less importance for the flavor and fragrance industry, 
though, its sterically demanding side chain gives more insights into the substrate diversity of the 
myxobacterial P450s. As shown in the supplemental data (4.1.1.1), several more P450s from So 
ce56, as published in 2.3, were tested for their conversions of the selected apocarotenoids. 
Interestingly, CYP109C1 is the only P450, which is not converting any of these compounds. All 
remaining P450s convert at least one compound, albeit in low amounts. This class of substrates 
might be structurally similar to some of their natural substrates, which are not known yet. 
However, it is described that So ce56 contains a putative carotenoid gene cluster and, hence, 
there is a strong probability that the P450s are exposed to carotenoids as well as their 
corresponding degraded products (Schneiker et al. 2007). Another explanation might be the 
structural valuable properties of these compounds. Such molecules can access the active site of 
most P450s, due to their small size. Furthermore, they possess several functional groups such as 
the α-,β-unsaturated ketone and the cyclohexene moiety (see Figure 7 A and B), which enable 
diverse docking positions. Moreover, the rigid side chain and more flexible ring structure might 
simplify the correct substrate orientation turning such compounds into promising substrates. 
Previous studies with myxobacterial P450s have shown that the amino acids of the active site 
form a hydrogen bond with the keto-group of the substrate (either His94 for CYP109D1 or 
Thr285 for CYP264B1), whereby the required substrate orientation is created (Khatri et al. 2010a; 
Ly et al. 2012). However, the alignment of the most valuable P450s tested in this study 
(CYP260B1 and CYP267B1) with CYP264B1 and CYP109D1 do not show high sequence identities. 
There is only a maximum of 33% and the corresponding residues are not highly conserved in 
these myxobacterial P450s (see supplemental 4.1.1.3 and 4.1.1.4). As a result, the sequences of 
these P450s cannot be taken into account and separate homology models need to be created. In 
the case of CYP260B1, the substrate-free crystal structure will be available soon and docking 
studies might give details about the amino acids involved in the substrate orientation. 
 
Figure 7: Structures and numbering of damascones (A) and ionones (B). The location of the double bond 
is represented by a greek letter (as shown in red, blue and magenta).    
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CYP260B1, CYP264A1 and CYP267B1 are capable of the conversion of all tested norisoprenoids. 
However, only CYP267B1 showed a high selectivity for nearly all tested compounds towards a 
single product. In contrast, CYP260B1 showed the highest yields of all P450s during this study but 
a high selectivity was just achieved towards β-ionone, β-damascone and δ-damascone. 
CYP264A1 showed the lowest yields and selectivities out of these three P450s and was, 
therefore, not further investigated.  
The steric of the side chain in position 6 influences the conversion significantly as shown for the 
methyl-substituted compounds being less converted than their non-substituted counterparts 
(see supplemental 4.1.1.1). Allyl-α-ionone (see Figure 7B [R=allyl]) demonstrates this observation 
even better, since most of the P450-dependent conversions show only traces of products. This 
compound is only converted by CYP260B1 and CYP267B1 in higher amounts. As a result, 
CYP260B1, CYP267B1 as well as CYP267A1 (known for its conversion of sterically demanding 
compounds like thioridazine) were chosen for the conversion of retinol (vitamin A1). This 
sterically more demanding compound (polyunsaturated side chain at position C6) is not 
converted by any P450 indicating the sensitivity of the P450s towards the length of the side 
chain. Besides the steric effects, the location of the keto group influences the conversion as 
shown for the damascones (see Figure 7 A). CYP109C2, for example accepts only compounds 
with a keto-group at position C7 as substrate. In contrast, most of the tested P450s prefer the 
substrates of the ionone-type with a keto-group at position C9 (see supplemental 4.1.1.1). An 
increased distance between the keto moiety and the ring seems to facilitate the correct 
substrate orientation, since all known products show an endocyclic oxyfunctionalization. Most 
myxobacterial P450s showed the hydroxylation at allylic position as main catalytic activity (data 
not shown). Such hydroxylations are preferred by many P450s, since C-H bonds in this specific 
position are very reactive caused by their low bond-dissociation energy (Ortiz de Montellano 
2010). The endocyclic epoxidation of β-ionone as main catalytic activity of CYP260B1 is thereby 
an exception. Those epoxy-products are not of high interest for biotechnological applications, 
since the corresponding compounds are easily formed by autoxidation processes under light 
exposure (Gagarina et al. 1984) or by chemical synthesis with mCPBA (meta-chloroperoxybenzoic 
acid) (Barakat et al. 2008). However, the question about the factors effecting the allylic 
hydroxylation versus the epoxidation of the double bond is not clarified in detail and still topic of 
researches (de Visser et al. 2002; Ilie et al. 2015). CYP260B1 catalyzes both reactions, 
hydroxylation and epoxidation, whereby the epoxidation is formed predominantly. Further 
studies about the substrate orientation of β-ionone in CYP260B1 as well as protein engineering 
towards a high selectivity of a certain reaction type might give deeper insights in this topic. 
Moreover, to the best of our knowledge, this is the first report of a specific P450 capable of the 
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epoxidation of an ionone-type structure (see Figure 8, right side), even P450BM3 mutants are not 
known for this type of reaction towards α- and β-ionone (Watanabe et al. 2007).  
Taken together, the myxobacterial P450s from So ce56 represent a promising tool for the 
oxyfunctionalization of carotenoid-derived aroma compounds. Figure 8 shows a toolbox towards 
the selective oxyfunctionalization of β-ionone. CYP109D1 and CYP267B1 form the endocyclic 
allylic alcohol, CYP260B1 forms predominantly the epoxy product and CYP264B1 forms the 3-
hydroxy product. 
 
Figure 8: Toolbox of myxobacterial P450s towards the selective oxyfunctionalization of β-ionone. The 3-
OH-β-ionone and 4-OH-β-ionone products formed by CYP264B1 and CYP109D1 were identified in 
previous studies by our group (Khatri et al. 2010a; Ly et al. 2012).  
 
 
3.2 Terpenes and terpenoids as substrates 
Terpenes and terpenoids represent  the largest class of natural products with over 40,000 known 
compounds (Withers and Keasling 2007). Most of them were isolated from plants but also from 
animals and microorganisms. They are classified as primary metabolites necessary for cellular 
functions and maintenance as shown for gibberellins, carotenoids and sterols as well as 
secondary metabolites known for their use as flavor and color enhancers, agricultural chemicals 
or pharmaceuticals (Roberts 2007; Rasool and Mohamed 2015). Their selective 
oxyfunctionalization is difficult to achieve with chemical syntheses caused by the complex 
structure of the substrates and the resulting low regio-, and stereoselectivity. The involvement of 
P450s in the biosynthesis of terpenoids is already studied for several mono- and sesquiterpenes, 
thus, P450s are an efficient alternative for the production of oxygenated terpenes (Weitzel and 
Simonsen 2015). Employing plant P450s for such an approach has the advantage that the natural 
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P450 capable of the desired reaction is used. However, the membrane-anchor of these P450s 
needs to be removed to solubilize them and to simplify, therefore, their expression in 
prokaryotes (Pateraki et al. 2015). Bacterial P450s represent a valuable substitute concerning 
their solubility and higher activity. There are several examples of terpenoids produced by 
bacterial P450s such as camphor, vitamin D3 or pravastatin (Janocha et al. 2015). In our studies, 
two P450s were investigated with four different sesquiterpene structures of the eremophilane-, 
humulane-, caryophyllane- and cedrane-type (see 2.2). CYP264B1 was chosen because of its 
function as terpene hydroxylase and CYP260A1 was selected, since it is known for the conversion 
of nootkatone (Ewen et al. 2009; Schifrin et al. 2015). Interestingly, CYP260A1 accepts only 
oxygenated compounds as substrates, whereas CYP264B1 accepts all kinds of substrates. 
CYP264B1 is located close to a terpene synthase in the genome of So ce56 and its natural 
function is the hydroxylation of eremophilene (Schifrin et al. 2015). Thus, it is not surprising that 
non-oxygenated compounds act as substrates. Furthermore, CYP264B1 shows a higher selectivity 
towards a single main product compared with CYP260A1, which is capable of the formation of a 
variety of products. The main products formed by CYP264B1 were identified as compounds 
predominantly hydroxylated in allylic position. In contrast, CYP260A1 did not show a main 
reaction type; hydroxylation, epoxidation and reduction of the double bond were identified, 
whereby the reduction may be caused by a consecutive reaction formed by enzymes from E. coli. 
Taken together, CYP264B1 is a potent enzyme for the oxyfunctionalization of terpenes and 
CYP260A1 might be a promising candidate for the introduction of additional oxygen atoms into 
terpenoids. 
Besides CYP260A1 and CYP264B1, several other myxobacterial P450s were tested with the 
terpenes τ-muurolol and β-phellandrene, whereby some of them were able to convert these 
substrates (see supplemental 4.1.2). However, none of the P450s showed a high selectivity 
towards a single main product and hence, the products were not available in sufficient amounts 
for structure elucidation. In addition, CYP267A1 and CYP267B1 were tested for their ability to 
convert nootkatone. The in vitro reactions showed that CYP267A1 was capable of the production 
of a single compound, whereas CYP267B1 formed predominantly two main products. However, 
the corresponding products were not scaled up by the utilization of the whole-cell system nor 
identified due to the time limit of this work. Nevertheless, those examples indicate the potential 
of the myxobacterial P450s to act as terpene/terpenoid oxidase and these first results might 
serve as good starting point for further experiments towards this large class of substrates.  
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3.3 Drugs as substrates 
Drugs are mainly metabolized in the liver by diverse P450s, whereby CYP1A2, CYP2C9, CYP2C19, 
CYP2D6, and CYP3A4 play the most important roles. Studies about the excretion of the drugs and 
the formation of metabolites are essential for the development, establishment and approval of 
novel drugs. Furthermore, drug metabolites formed greater than 10 % at steady state or total 
drug exposure need to be investigated in toxicological tests according to the Food and Drug 
administration or European Medicines agency guidelines, respectively (FDA 2008; ICH 2009). To 
obtain sufficient amounts of metabolites for such tests, efficient ways for the selective 
production of certain metabolites are requested. Liver P450s can be applied for this purpose but 
they are often capable of the formation of a variety of compounds. Furthermore, the activities 
and expression levels of mammalian P450s are often limited in a reconstituted system. In 
contrast, bacterial P450s have the benefits of a high activity and high expression levels. 
Moreover, the solubility and high stability simplifies their handling for biotechnological 
applications (Bernhardt 2006). Hence, there are several reports of bacterial P450s performing the 
production of specific drug metabolites, whereby P450BM3 represents the best studied one 
(Julsing et al. 2008; Fasan 2012; Whitehouse et al. 2012; Kang et al. 2014; Kulig et al. 2015; Ren 
et al. 2015). Myxobacterial P450s are known to be involved in the formation of secondary 
metabolites of structurally complex compounds such as epothilones and might, therefore, act as 
drug metabolizers. For that reason, several classes of drugs, which are known to be converted by 
mammalian P450s, were chosen (see 2.4 and supplemental 4.1.4) for an initial in vitro screening, 
since spin shift experiments are often not significant because nitrogen containing compounds 
often lead to a type-II shift besides acting as substrate (Locuson et al. 2007). During the in vitro 
experiments, the CYP267 family, CYP260A1 and CYP264A1 were identified as potential drug 
metabolizers. The CYP267 family represents the most promising P450s with a very high substrate 
range, however, their activity is low and, therefore, the product identification is hindered (see 
2.1 and 2.4). Likewise, CYP260A1 acts as drug metabolizer but its activity is also very low towards 
most of these compounds. On the other hand, CYP264A1 showed higher yields towards the 
conversion of some tricyclic psychotherapeutics. Since 4-methyl-3-phenyl-coumarin (also a 
tricyclic compound) was known so far as sole substrate, it seems that this P450 prefers cyclic 
compounds as substrate. To verify this assumption, several other tricyclic antidepressants and 
antipsychotics as well as their corresponding precursors were tested (see 2.1). Some of these 
compounds were converted by CYP264A1, whereby the side chain plays an important role. The 
dimethyl-amino-propyl group seems to be necessary for an efficient conversion, since the 
precursors lacking the side chain were not converted in higher amounts. Promethazine 
possessing a dimethyl-amino-isopropyl side chain is also not converted, verifying the high 
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sensitivity of CYP264A1 towards the side chain of these compounds. Besides the typical 
production of more hydrophilic compounds, CYP260A1 was capable of the formation of several 
compounds more hydrophobic than the substrate. One of the products formed by the conversion 
of promethazine showed the same retention time as phenothiazine leading to the assumption 
that the side chain was degraded or cleaved, respectively. A dealkylation of the side chain of such 
drugs is to the best of our knowledge not described yet. However, this product was not obtained 
in higher amounts by the whole-cell system, so that the product identification was not verified by 
NMR spectroscopy and further analyses by HRMS or MSn-experiments are necessary to 
characterize the product in detail.  
Other groups also tried to find bacterial drug metabolizing P450s besides P450BM3. For example, 
Kulig et al. fused diverse P450s from Rhodococcus jostii RHA1 with the P450 reductase domain 
(RhfRED) of cytochrome P450Rhf from Rhodococcus sp. NCIMB 9784 and tested them as drug 
metabolizers. One fusion protein, named Ro07-RhfRED, showed a demethylation activity towards 
imipramine and related compounds and might be used to produce the corresponding 
demethylated metabolites (Kulig et al. 2015). Interestingly, CYP264A1- and CYP267B1-dependent 
reactions achieved the 10-hydroxy derivatives of imipramine and some of its analogs. 
Additionally, CYP267A1 was able to convert the sterically more demanding thioridazine, albeit in 
lower amounts. The regioselectivity is, thereby, the same for CYP267A1, CYP267B1 and 
CYP264A1, since all tested P450s functionalized the middle ring. CYP264A1 was capable of the 
production of these metabolites in a milligram per liter scale during the whole-cell processes, 
whereas CYP267B1-dependent conversions showed considerably lower yields. However, 
optimizations of the whole-cell systems led to higher yields for the CYP267 family (see 2.4) but 
further improvements like protein engineering are required to apply these P450s for 
biotechnological applications. Nevertheless, these examples substantiate the potential of 
bacterial P450s for the production of specific drug metabolites. 
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3.4 Establishment of a whole-cell system for myxobacterial P450s towards a preparative 
scale 
The whole-cell system previously developed by our laboratory enables the production in a more 
preparative scale and is suitable for some of the myxobacterial P450s (Ringle et al. 2013). 
However, our studies demonstrated that further improvements for several P450s are needed to 
produce sufficient amounts of products for structure elucidation via NMR spectroscopy. 
Furthermore, a higher productivity towards a preparative scale of several hundred milligrams per 
liter is requested for biotechnological processes. To reach such a goal, several optimization 
strategies can be applied, whereby improvements can be performed by altering the properties of 
the proteins as well as changing the conditions of the whole-cell system. 
 
3.4.1 Improvements of the gene expression, P450 activity and electron transfer 
Since we are working with wild type enzymes, protein engineering would be a good starting point 
to optimize the productivity. Site directed mutagenesis and laboratory evolution are very 
common methods to improve the properties of P450s (Gillam 2008). Wild type enzymes often 
show a low activity towards their non-natural substrates and, therefore, optimizations towards 
their activity are essential for biotechnological relevant processes. Furthermore, improvements 
concerning the regioselectivity and reaction type would be necessary for some of the 
myxobacterial P450s. CYP260B1 for example, is very unselective for several norisoprenoid 
substrates (see 2.3) and improvements towards a higher selectivity are necessary to produce a 
single compound. The crystal structure of this P450 will be available soon and as a result, site 
directed mutagenesis might be the most promising approach to achieve a higher selectivity. The 
crystal structures of CYP260A1 and CYP109D1 are also close to be finished, however, resolving 
the crystal structures of the other P450s is not in progress yet. Nevertheless, computer aided 
mutagenesis approaches or laboratory evolution can be used for proteins, whose three-
dimensional structures are not known. Low concentrations of the corresponding P450 in the 
whole-cell system might also be critical, whereby altering the cells lines or expression plasmids 
can lead to higher expression levels of the P450s (Zelasko et al. 2013). Additionally, the genes 
encoding the P450 might be improved by codon optimization, which was already successfully 
done for CYP264B1, leading to an improved expression level (Schifrin et al. 2015). The availability 
of sufficient amounts of the cofactor might be another problematic issue, especially for 
conversions with a lower coupling efficiency. The expression of a dehydrogenase capable of the 
recycling of NAD(P)H can, therefore, lead to an increased product formation (Schewe et al. 2008). 
Furthermore, the efficiency of the redox partners need to be optimized for each P450 
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individually, since not all P450s prefer the same redox partners as shown for CYP267B1 and 
CYP260A1. CYP267B1 shows a higher efficiency with the natural electron transfer partners Fdx8 
and Fdr_B, whereas CYP260A1 prefers the heterologous redox partners Adx4-108 and AdR (Ewen et 
al. 2009; Khatri et al. 2010b; Kern et al. 2015). The influence of the electron transfer partners was 
also demonstrated for the CYP21A2-dependent whole-cell process for the production of 
premedrol by our labrartory (Brixius-Anderko et al. 2015). As a result, the selection of redox 
partners is a critical factor for the optimization of a whole-cell system. Furthermore, the electron 
transfer from the ferredoxin to the P450 is known as rate limiting step in the electron transport 
chain and the expression of additional ferredoxin by introducing two or more copies of the 
ferredoxin cDNA into the plasmid can lead to improved yields (Ewen et al. 2012; Schiffer et al. 
2015b). 
 
3.4.2 Improvements of the conditions for the whole-cell system  
The substrate uptake of the cells is often a limiting step in the establishment of a whole-cell 
system. Cell permeabilizing compounds like EDTA, polymyxin B, toluol, Tween 20 or CTAB (N-
cetyl-N,N,N-trimethylammonium bromide) can be applied to ensure the substrate availability in 
the cells (Janocha and Bernhardt 2013). This problem was also shown for the conversion of the 
tricyclic drugs, which was solved by the addition of EDTA increasing the substrate availability (see 
2.1). Another common issue in E. coli based whole-cell systems is the occurrence of indole, an 
inhibitor for many P450s as shown for CYP267A1 and CYP267B1 (see 2.4). In E. coli, the enzyme 
tryptophanase produces indole from tryptophan decreasing the efficiency of biocatalytic P450 
processes dramatically (Li and Young 2013). For that reason, complex media are often not 
suitable for E. coli based whole-cell systems harboring P450s. There are two common approaches 
to overcome this problem by either using medium, which only contains a minimum of 
tryptophan, or applying resting cells in buffer. As shown in 2.1, both approaches enable the 
production of the drug metabolites, however, there are significant differences in the productivity 
of both systems. A close correlation between the tested P450s and the conversion of the 
compounds was not observed. Hence, the application of resting cells in buffer or growing cells in 
medium need to be tested for each system individually. An additional bottleneck for P450-based 
bioconversions is the solubility of the substrates caused by their strong hydrophobic character. 
Several solvents like ethanol, DMSO or derivatives of β-cyclodextrin (complexing of substrates) 
might be tested for their influence on the conversion (Schulz et al. 2015). Furthermore, a biphasic 
system consisting of water containing the cells and a layer of organic solvent as reservoir for the 
substrates can be used. Thereby, the organic phase allows the accumulation of oxygenated 
products and hinders overoxidation. Moreover, inhibitory and toxic effects of the substrates as 
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well as products are minimized in a biphasic system. The efficiency of such an approach was 
already demonstrated for the conversion of terpenes and steroids (Girhard et al. 2009; Braun et 
al. 2012). Besides all these examples, there are several additional bottlenecks for the 
development and implementation of a whole-cell system. A recently published review by 
Lundemo and Woodley describes the most common challenges and solutions for the 
establishment of whole-cell P450 catalyzed reactions in more detail (Lundemo and Woodley 
2015). 
 
 
3.5 Potential natural functions 
In this study, compounds out of different classes of substrates such as apocarotenoids, 
sesquiterpenes, aromatic compounds and drugs were tested with nine of the myxobacterial 
P450s. Thereby, we found ionones, damascones, cedrenol, zerumbone, cinnamaldehyde as well 
as several drugs such as the tricyclic psychotherapeutics as novel substrates for some of the 
P450s. Moreover, we identified several products and got a first overview of the substrate ranges 
and selectivities for these P450s (see Table 1) leading to some speculations about their 
physiological roles.  
The CYP109 family consists of three members, which are clustered with carbohydrate-
metabolism related genes (CYP109C1), regulatory elements (CYP109C2) or unique proteins 
(CYP109D1), respectively (Khatri et al. 2011). These P450s are known for the binding and 
conversion of fatty acids and, in addition, CYP109D1 is known for the conversion of α- and β-
ionone (Khatri et al. 2010a; Khatri et al. 2013). Due to their low substrate range, it is not 
surprising that for CYP109C1 no novel substrates were found, for CYP109C2 only damascones act 
as substrate and just CYP109D1 converted several carotenoid-derived aroma compounds as well 
as cinnamaldehyde. CYP109B1 from Bacillus subtilis revealed also a small substrate range, since 
only fatty acids, ionones, indole and nootkatone were identified as substrates (Girhard et al. 
2010). This observation indicates that the CYP109 family seems to have a specific function in the 
metabolism of a certain compound and might not be capable of the degradation of xenobiotics. 
Thereby, the preference towards small cyclic compounds and fatty acids of the CYP109 family 
might lead to the conclusion that they are involved in the biosynthesis of such compounds.  
The CYP260 family shows a much broader substrate diversity, ranging from terpenoids (see 2.2) 
and apocarotenoids (see 2.3) to drugs (see 2.1 and supplemental 4.1.4) and steroids (Khatri et al. 
2015). However, all compounds need to be oxygenated to act as substrate for this family as 
shown during all studies. Interestingly, besides belonging to the same family, both P450s differ 
very much in their substrate range. CYP260B1 converts apocarotenoids with a high yield, 
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whereas CYP260A1 produces only low amounts of products. In contrast, CYP260A1 is more 
potent towards drugs, albeit the activity is very low. The aromatic compound cinnamaldehyde is 
converted by CYP260B1 producing the corresponding acid, whereas CYP260A1 only shows a very 
low activity towards this compound. The formation of cinnamic acid out of cinnamaldehyde is an 
uncommon reaction, since the structurally similar apocarotenoids are oxygenated at the ring 
moiety by CYP260B1. This reaction also occurs after the exposure to air and during all 
conversions, low amounts of cinnamic acid were detected. However, CYP260B1 converted most 
of the aldehyde to the acid and we presumed that the formation of hydrogen peroxide might be 
responsible for the reaction. However, the addition of H2O2 to the reaction mixture did not result 
in a conversion, disproving the assertion of a H2O2-driven reaction. Furthermore, cinnamyl 
alcohol, also known for its autoxidation (Niklasson et al. 2013), did not show any product 
formation verifying that the reaction is H2O2 independent. Spectral analyses showed a typical 
type-I shift for the aldehyde, whereas the alcohol and the acid did not show any shifts (data not 
shown). Therefore, this reaction is of interest for studying the interaction between the amino 
acids of the active site and the moieties of the substrate. The crystal structures of CYP260A1 and 
CYP260B1 will be available soon and docking studies of cinnamylaldehyde might give more 
details about this uncommon reaction. The comparison of the interactions of cinnamaldehyde, 
the apocarotenoids as well as some of the drugs with both P450s might identify the differences 
in the SRSs of this family and, therefore, their diverse substrate range. The physiological roles of 
the CYP260 family might be related to the degradation of xenobiotics due to their broad 
substrate range. Moreover, they could be involved in the functionalization of secondary 
metabolites. Since only oxygenated compounds are accepted as substrates, the functionalization 
would be more probably in a late state of the biosynthesis.  
The CYP264 family consists of two members, CYP264A1 and CYP264B1, which show a diverse 
substrate range. CYP264B1 is clustered to a terpene synthase in the genome of So ce56 and 
hence, its natural function is presumed as terpene hydroxylase (Khatri et al. 2011). Previous 
studies by our laboratory proved this assumption by identifying CYP264B1 as efficient 
hydroxylase for the sesquiterpene (+)-eremophilene (Schifrin et al. 2015). The conversion of 
further sequiterpenes based on eremophilane, humulane, caryophyllane and cedrane resulted 
predominantly in a main product hydroxylated in allylic position as well as some unknown side 
products (see 2.2). In contrast, the physiological role of CYP264A1 is not known and cannot be 
hypothesized, since it is clustered in open reading frames (ORFs) encoding hypothetical proteins 
(Khatri et al. 2011). During previous studies, only a derivative of coumarin was identified as 
substrate (Ringle et al. 2013). In this study, several novel substrates such as tricyclic drugs and 
apocarotenoids were identified (see 2.1 and supplemental 4.1.1.1). Only cyclic compounds seem 
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to act as substrate for this enzyme, whereby tricyclic compounds showed a higher selectivity 
towards a single main product. Homocyclic and heterocyclic compounds are both accepted by 
this P450 and hydroxylation as well as sulfoxidation is observed as catalytic activity towards the 
tricyclic drugs. In contrast, CYP264B1 did not show any activity towards the tricyclic drugs, 
although, having a similar size than sesquiterpenes. The low flexibility of the aromatic rings in the 
drugs might hinder the binding and, therefore, the conversion compared to the non-aromatic 
terpene structures possessing a more flexible structure. Interestingly, all tested carotenoid-
derived aroma compounds were converted by CYP264A1, whereby β-damascenone showed the 
highest yields. This observation shows the preference of CYP264A1 towards cyclic substrates with 
a less flexibility leading to the assumption that CYP264A1 is involved in the biosynthesis of cyclic 
or particularly tricyclic compounds with a rigid structure.  
The CYP267 family showed the widest substrate range of all tested myxobacterial P450s and is, 
therefore, a promising enzyme family for different kinds of biotechnological approaches. The 
tested substrates range from structurally diverse drugs (see 2.1 and 2.4) to simple structures like 
the carotenoid-derived aroma compounds (see 2.3). Although showing a broad substrate range 
and high selectivity, these family members show a quite low activity towards most of the 
substrates. Thereby, CYP267B1 converts more substrates and shows a higher activity compared 
to CYP267A1. Nearly all tested apocarotenoids are converted to the allylic alcohols by CYP267B1, 
whereas CYP267A1 did not show high activities and selectivities towards most of these 
compounds. Interestingly, CYP267A1 was capable of the sulfoxidation of thioridazine, a sterically 
more demanding compound that was not converted by CYP267B1. However, another study by 
our laboratory identified epothilone D as substrate for CYP267B1 indicating that both enzymes 
have the ability to convert sterically more demanding compounds (Kern et al. 2015). Thus, this 
family is capable of the conversion of small (like ionones and damascones) and large molecules 
(like thioridazine or epothilone D) as well as structurally diverse compounds (see 2.4) making it 
difficult to assume about the physiological role. Moreover, the diverse reaction types such as 
aliphatic hydroxylation, aromatic hydroxylation, alcohol oxidation and sulfoxidation do not give a 
hint about their natural functions (see 2.1, 2.3 and 2.4) (Kern et al. 2015). In the genome, 
CYP267A1 is clustered with carbohydrate-metabolism related genes, so its natural function might 
be bound up with using different carbon sources for growth. In contrast, CYP267B1 is clustered 
with some hypothetical proteins, which does not give any clue about its physiological role (Khatri 
et al. 2011). However, such a broad substrate range and variety of reaction types might indicate 
that these P450s are involved in the degradation of xenobiotics similar to the liver P450s CYP3A4 
or CYP2D6. Interestingly, there is only a low number of bacterial P450s showing a similar broad 
substrate range like P450BM3 or CYP116B4 from Labrenzia aggregata (Whitehouse et al. 2012; Yin 
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et al. 2014). These specific properties turn this family into promising biocatalysts for the 
development of biotechnological processes. 
 
Table 1: Investigated myxobacterial P450s, their substrate range, novel substrates identified in this study 
as well as their performed reaction types. 
P450 Substrate range Novel substrates found during 
this work 
Main reaction types 
CYP109C1 No substrate 
known 
- - 
CYP109C2 Small cyclic 
compounds 
Damascones  n.d. 
CYP109D1 Small cyclic 
compounds 
Derivatives of ionones, 
damascones as well as 
cinnamaldehyde 
Allylic hydroxylation 
CYP260A1 Oxygenated 
compounds 
Oxygenated drugs and 
sesquiterpenes 
Hydroxylation, epoxidation 
CYP260B1 Oxygenated 
compounds 
Ionones and derivatives of 
them, damascones as well as 
cinnamaldehyde 
Hydroxylation, epoxidation, 
aldehyde oxidation 
CYP264A1 Cyclic compounds Ionones and derivatives of 
them, damascones as well as 
tricyclic drugs 
Hydroxylation, sulfoxidation 
CYP264B1 Terpenes and 
terpenoids 
Ionones and derivatives of 
them as well as damascones  
Allylic hydroxylation 
CYP267A1 Drugs, terpenes, 
terpenoids and 
apocarotenoids 
Ionones and derivaties of 
them, damascones, diverse 
drugs, terpenes and 
terpenoids 
Allylic  hydroxylation, 
sulfoxidation 
CYP267B1 Drugs, terpenes, 
terpenoids and 
apocarotenoids 
Ionones and derivaties of 
them, damascones, diverse 
drugs, terpenes and 
terpenoids 
Aliphatic and aromatic 
hydroxylation, allylic 
hydroxylation, sulfoxidation 
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Taken together, several classes of potential substrates for the myxobacterial P450s were 
screened in this work. Those systems showing a highly selective in vitro conversion towards a 
single main product were scaled up in an E. coli based whole-cell system and the purified 
products were analyzed by NMR spectroscopy. During these studies, apocarotenoids were 
identified as substrates efficiently converted by CYP260B1, CYP264A1 and CYP267B1, whereby 
several products of the CYP260B1- and CYP267B1-dependent conversions were characterized. 
CYP267B1 showed the typical allylic hydroxylase activity, whereas CYP260B1 showed an 
additional epoxidase activity towards some of the tested compounds. Such an epoxidase activity 
towards β-ionone as well as the methyl-substituted derivatives of α-ionone is to the best of our 
knowledge not known for any specific P450. Moreover, some novel products such as 2-OH-δ-
damascone, 3-OH-allyl-α-ionone and 4-OH-allyl-β-ionone were identified. Aromatic compounds 
(see supplemental 4.1.3) were also tested in this study but did not serve as substrates for most of 
the P450s. Cinnamaldehyde was the only compound out of this class, which acts as substrate for 
CYP109D1 and CYP260B1, whereby the activity of CYP109D1 was too low to characterize the 
corresponding product. In contrast, the product formed by CYP260B1 was obtained in sufficient 
amounts for NMR analysis and thereby, elucidated as cinnamic acid. Furthermore, several 
structural diverse drugs were tested as potential substrates, whereby CYP260A1, CYP264A1, 
CYP267A1 as well as CYP267B1 were identified to act as drug metabolizers. CYP260A1 accepted 
only oxygenated drugs as substrates but its activity was too low to characterize the 
corresponding products. However, the comparison of the retention times with phenothiazine as 
standard gave a first clue about the possible degradation of the side chain of promethazine. 
Additionally, the CYP267 family was identified as highly versatile drug metabolizers. Moreover, 
CYP264A1 converted the tricyclic psychotherapeutic drugs amitriptyline, clomipramine, 
chlorpromazine and imipramine in a milligram per liter scale. Thereby, the same metabolites as 
those formed by human liver P450s were obtained. This was the first report about the 
production of pharmaceutically important compounds by a myxobacterial P450 from So ce56. 
The largest class of substrates tested in this study belongs to the terpenes and terpenoids. The 
sesquiterpenes cedrenol and zerumbone were identified as novel substrates for CYP260A1. The 
selectivity of this P450 was not high, however, several new products were characterized. 
Moreover, some other terpenes and terpenoids such as nootkatone, τ-muurolol or β-
phellandrene were identified as substrates for CYP267A1 and CYP267B1. The products were not 
elucidated during this study due to the time limit of this thesis, nevertheless, this preliminary 
work might serve as good starting point for further studies. 
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3.6 Outlook 
The obtained results demonstrate the substrate range and catalytic activity of the selected 
myxobacterial P450s. During this work, 9 out of the 21 P450s from So ce56 were investigated, 
whereas the remaining 12 P450s are still not characterized. Most of the latter ones show a low 
expression rate and hence, the expression and purification of these P450s is not efficient. 
Increasing the expression rate by optimization of the expression conditions or the change to a 
pET-system might lead to sufficient amounts of pure protein for further characterization. These 
unknown P450s may also reveal unique and novel activities. A high throughput screening 
towards a ligand library checking the spectral shifts would be helpful to identify potential 
substrates for these P450s as demonstrated for CYP260A1 (Khatri et al. 2015). New P450s with 
novel properties are valuable as shown for their increasing importance in the field of 
biotransformation (Meyer et al. 2013). 
Some of the products identified in this study are of biotechnological interest such as the drug 
metabolites or the functionalized apocarotenoids, however, the optimization of the whole-cell 
system towards a preparative scale is required. Drug metabolites are often used in toxicological 
tests or as authentic standard for analytical studies, whereby amounts from a low milligram to 
gram scale are needed. Fine chemicals such as the functionalized apocarotenoids are used as 
building blocks and, therefore, amounts in a gram scale are required. To achieve this goal, 
optimizations like protein engineering or exchange of the redox partners are necessary. Higher 
amounts of products would enable diverse synthetic routes or chemoenzymatic approaches for 
the development of novel compounds with altered characteristics. Nevertheless, the already 
obtained products might be applied for some further characterization like testing the odor 
properties of the apocarotenoid-products, which only requires a few milligrams of substance.  
The identified substrates can also be used to characterize the P450s in more detail. 
Crystallization of the P450s in a substrate-bound form will now be available for several more 
P450s. The structural analyses would give detailed insights in the active sites of the P450s. The 
crystallization of the CYP267 members with structurally diverse substrates would be of high 
interest, since these P450s show a broad substrate range.  Such an approach might be useful to 
explore the flexibility of the active site as well as the SRSs. Another interesting issue would be the 
crystallization of CYP260B1 with β-ionone as substrate. The crystal structure may be used to 
identify the amino acids and docking positions responsible for the reaction type. Site directed 
mutagenesis of these specific amino acids could help to investigate the question about the 
factors influencing the epoxidation versus the allylic hydroxylation. 
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Furthermore, testing several more substrates or substrate classes may identify some more 
interesting reactions and products. Some terpenes and terpenoids were already tested in this 
study, however, their corresponding products were not elucidated due to the time limit of this 
thesis. These initial tests identified activities of the CYP267 family members towards nootkatone, 
τ-muurolol or β-phellandrene. As a result, CYP267A1 and CYP267B1 may be promising candidates 
to act as terpene/terpenoid-oxidase. This preliminary work might be used for further studies 
towards this large class of substrates that is of particular interest for the production of flavor and 
fragrance as well as pharmaceutical compounds. 
The identification of their physiological roles is another important topic, which should be 
investigated in more detail. Analyses of the genomic context were already done but potential 
functions are just presumed and need to be proven (Khatri et al. 2011). The reconstitution of the 
biosynthetic gene clusters involved in the secondary metabolite formation might elucidate the 
physiological roles of the P450s. However, such an approach is only feasible for the P450s 
CYP263A1 and CYP265A1, since solely these P450s are clustered with genes potentially involved 
in the secondary metabolite formation. Another approach could be the knockout of specific 
P450s to check if their biodiversity is bound up with using different carbon sources for growth. 
CYP109C1 and CYP267A1 are clustered with carbohydrate-metabolism related genes. The 
knockout of their corresponding genes might influence the growth of the bacterium on diverse 
carbon sources. Moreover, improved analytic studies concerning the metabolomics might lead to 
the identification of diverse secondary metabolites as well as their intermediates. A comparison 
of those metabolites with the substrates and products characterized in this study may identify 
structurally similar compounds. Such an approach could be used to specify their physiological 
roles. 
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4 Appendix 
4.1 Supplemental data 
4.1.1 Carotenoid-derived aroma compounds as substrates 
4.1.1.1 Screening of carotenoid-derived aroma compounds  
The carotenoid-derived aroma compounds were screened with CYP109C1, CYP109C2, CYP109D1, 
CYP260A1, CYP264A1, CYP264B1 and CYP267A1 and analyzed by GC-MS as shown before (see 
2.3). 
Table 2: Screening of carotenoid-derived aroma compounds with selected P450s from So ce56. Conversions 
are marked with – (no conversion), + (<10%), ++ (<50%), +++ (>50%), us (unselective product formation, 3 or 
more products) and s (selective, maximum of 2 products). 
substrate CYP109C1 CYP109C2 CYP109D1 CYP260A1 CYP264A1 CYP264B1 CYP267A1 
α-ionone - - ++ (s)  
(Khatri et 
al. 2010a) 
+ (us) + (us) ++ (s) 
(Ly et al. 
2012) 
++ (us) 
β-ionone - - ++ (s)  
(Khatri et 
al. 2010a) 
++ (s) ++ (s) ++ (s) 
(Ly et al. 
2012) 
++ (s) 
Dihydro-α-ionone - - + (s) + (us) ++ (us) + (us) ++ (us) 
Dihydro-β-ionone - - + (s) ++ (s) ++ (s) - ++ (s) 
Methyl-α-ionone - - + (s) + (us) + (us) + (us) + (us) 
Isomethyl-α-ionone - - + (s) Traces of 
product 
+ (us) + (s) Traces of 
product 
Allyl-α-ionone - - Traces of 
product 
Traces of 
product 
+ (s) Traces of 
product 
Traces of 
product 
α-ionol - - + (s) + (us) + (us) Traces of 
product 
+ (us) 
β-ionol - - + (us) + (us) + (us) + (s) ++ (us) 
α-irone 
(diastereomeric 
mixture -> No 
selectivity determined) 
- - + + ++ + + 
α-damascone - + (s) + (s) + (us) ++ (us) - + (s) 
β-damascone - + (s) + (s) + (s) ++ (s) + (s)  + (s) 
δ-damascone - + (s) + (us) + (us) +++ (s)  + (us) + (us) 
β-damascenone - + (s) + (s) + (s) +++ (us) ++ (s) + (s) 
        
 CYP260B1 CYP267A1 CYP267B1 
Retinol* - - - 
* In vitro reactions were performed as described before (see 2.3), with the exception that retinol was dissolved in 
Tween80, ascorbic acid was added as radical scavenger and that the reaction was analyzed by HPLC-DAD. 
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4.1.1.2 Whole-cell conversions of carotenoid-derived aroma compounds 
 
During the whole-cell conversion of n-methyl-α-ionone by CYP267B1, an additional product 
was isolated in sufficient amounts for NMR-characterization and characterized as 3-keto-n-
methyl α-ionone: 
1H NMR (CDCl3): 6.68 (dd, 1H, H7), 6.18 (dd, 1H, H8), 5,96 (br s, 1H, H4), 2.69 (d, 1H, H6), 2.57 
(q, 2H, H10), 2.36-2.30 (m, 1H, H2a), 2.01 (d, 1H, H2b), 1.87 (d, 3H, Me5), 1.50 (s, 3H, Me1a), 
0.98 (s, 3H, Me1b); 13C NMR (CDCl3): 200.32 (C9), 198.32 (C3), 159.49 (C5), 142.58 (C7), 
132.88 (C8), 55.67 (C6), 47.60 (C2), 34.94 (C1), 33.84 (C10), 28.17 (Me1a), 27.54 (Me1b), 
23.74 (Me5), 8.17 (C11). 
 
The whole-cell conversion of α-ionone by CYP260B1 led to a variety of compounds. The 
purification of the products was not sufficient to characterize all compounds by NMR 
spectroscopy. Nevertheless, the epoxy product was also identified for non-substituted α-
ionone: 
1H NMR (CDCl3): 6.65 (dd, 1H, H7), 6.08 (d, 1H, H8), 3.08 (t, 1H, H4), 2.28 (s, H3, Me10), 2.06 
(d, 1H, H6), 1.90-1.83 (m, 2H, H3), 1.47-1.43 (m, 1H, H1a), 1.26 (s, 3H, Me5), 1.02-0.99 (m, 
1H, H1b), 0.91 (s, 3H, Me1a), 0.73 (s, 3H, H1b); 13C NMR (CDCl3): 197.78 (C9), 145.20 (C7), 
134.07 (C8), 59.49 (C4), 58.83 (C5), 52.44 (C6), 28.65 (C2), 28.44 (C1), 27.90 (Me1a), 27.48 
(Me1b), 26.39 (C10), 22.68 (C11), 21.70 (C3). 
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4.1.1.3 Comparison of CYP260B1 and CYP267B1 with CYP109D1  
 
CYP260B1      -----------------------MLPRKNLFSFTSKDPSAFGIHLAAAAREH-SVYFDEG 
CYP109D1      -METETAPSPSPEQIDLSAPSVIADPYPAYRALRGRSPVLYARV-PAGGAAG-LGEP--- 
CYP267B1      MVDQDA-------FPELFHPSSRAEPH-----------AIYARM-RAAGRLHRLVHPRLD 
                                                                          
 
CYP260B1      LGVPVVLRGADVVAVLRDSETFSTRT--------------YDTGIMKGALVTLGGEAHTR 
CYP109D1      IRAYALLRHAEVLAALRDPQTFS------SNVTD------KIRVLPRITLLHDDPPRHTH 
CYP267B1      VPIWVAVRYDDCVELLKDPRLIRDFRKLPDEVRRRYFPLSDRTTFMDQHMLDADPPDHTR 
                                   
CYP260B1      MRRLFNAVLSPRVISRYEEATVTPVARRVVERLVRKERAELFDDFAISMPMGVTSALFGL 
CYP109D1      LRRLVSRSFTPRRIAELEP-WIGRLAASLLEATGD-GPSDLMGAYAMPLPMMVIATLLGI 
CYP267B1      LRAIVQRAFSPRMMEGLRP-RIQEIADGLIDAVIDRRRMELIADFAFPLPTAVIAELLGL 
 
CYP260B1      PEERIAENDALIRKMIRSVVMPQDPVVVAEGRSAHAAMEAQLREIAEREVAHPSDTLLGE 
CYP109D1      PAERYVQFRSWSESVMS---YSGIPA--EERASRGKAMVDFFAAELEARRRAPSGDLISA 
CYP267B1      PVEDRGRFRRWTKILLA---PAKDREFVERAQPVVEEFAAYFRALADARRKAPRDDLISG 
 
CYP260B1      IARAIVAEGLGGVEACEGVVLTLILGSYETTSWMLANLLVALLAHPDAMNQLRQQPSLLP 
CYP109D1      LVEAEIDGARLDTPEAVGFCVGLLVAGNDTTTNLIGNMAHLLSERPELYRRAQQDRSLVG 
CYP267B1      LLLAEEQEHKLSPAELSSMVFLLLVAGHETTVHLIASGMLLLLSHPAERRRLDEDPGLVG 
 
CYP260B1      QAIEESTRWCSSAAG-IVRFVEREATIGGETLAAGTILYLSLIARHYDEEIYPRPETFDI 
CYP109D1      PIIEETLRHSSPVQR-LLRVTTRPVDVSGVMIPAGHLVDVVFGAANRDPAVFEEPDAFRL 
CYP267B1      SAVEEALRCEGPAELSTIRWSLEDIELFGARVPAGEGVAAGLLAANRDPQHFPDPDRFDI 
 
CYP260B1      HRRPVGMLNFGGGLHYCVGAPLARMEARVGVSLLLERFPALRADPTVQP-TFSTAP--RG 
CYP109D1      DRPPAEHLAFGQGTHFCIGAALARMEARIALNALLDCYESITPGE---------APPLRQ 
CYP267B1      GRSPNRHIGFGGGIHFCLGAMLARIEAAIAFSTLLRRLPRIELATSTRDIVWSEWPTIRG 
 
CYP260B1      A---AAFGPDQIPALLV------  ->28% identity 
CYP109D1      TRAIMPLGFESLPLVLRRSRATA   
CYP267B1      -PAAVPVVF--------------  ->33% identity 
 
 
4.1.1.4 Comparison of CYP260B1 and CYP267B1 with CYP264B1 
CYP260B1      ---MLPRKNLFSFTS-KDPSAFGIHLAAAAREHSVY-FDEGLGVPVVLRGADVVAVLRDS 
CYP264B1      ----MTRLNLFAPEVRENPYPFYAALRRESPVCQ----VDPNGMWVVTRYDDIVAAFKNT 
CYP267B1      MVDQDAFPELFHPSSRAEPHAIYARMRAAGRLHRLVHPRLDVPIWVAVRYDDCVELLKDP 
 
CYP260B1      ETFSTRT--------------YDTGIMKGALVTLGGEAHTRMRRLFNAVLSPRVISRYEE 
CYP264B1      QVFSSAGLR-M---ATEPPYLRRQNPLSGSMILADPPRHGQLRSISSRAFTANMVSTLEH 
CYP267B1      RLIRDFRKLPDEVRRRYFPLSDRTTFMDQHMLDADPPDHTRLRAIVQRAFSPRMMEGLRP 
 
CYP260B1      ATVTPVARRVVERLVRKERAELFDDFAISMPMGVTSALFGLPEERIAENDALIRKMI-RS 
CYP264B1      -HMRSMAVRLTDDLVHRRVVEFISEFASRAQVSVLAKLIGFDPGLEGHFKRWATDLVIVG 
CYP267B1      -RIQEIADGLIDAVIDRRRMELIADFAFPLPTAVIAELLGLPVEDRGRFRRWTKILLA-- 
 
CYP260B1      VVMPQDPVVVAEGRSAHAAMEAQLREIAEREVAHPSDTLLGEIARAIVAEGLGGVEACEG 
CYP264B1      VIPPEDHARIAEVRRTIDEMEQYMLGLLASRRRHLENDLVSELLRSRRDDDGITDQDLVS 
CYP267B1      --PAKDREFVERAQPVVEEFAAYFRALADARRKAPRDDLISGLLLAEEQEHKLSPAELSS 
 
CYP260B1      VVLTLILGSYETTSWMLANLLVALLAHPDAMNQLRQQPSLLPQAIEESTRWCSSAA-GIV 
CYP264B1      LLSLLLVAGLETSTSLMTHMVLILAQRPMWMDRLRAEPALIPHFIEEVMRFEAPVH-ATM 
CYP267B1      MVFLLLVAGHETTVHLIASGMLLLLSHPAERRRLDEDPGLVGSAVEEALRCEGPAELSTI 
 
CYP260B1      RFVEREATIGGETLAAGTILYLSLIARHYDEEIYPRPETFDIHRRPVGMLNFGGGLHYCV 
CYP264B1      RLTVTETELGGTRLPAHAVVALLISSGLRDEARFQEPDRFNPERGDQANLAFGHGAHFCL 
CYP267B1      RWSLEDIELFGARVPAGEGVAAGLLAANRDPQHFPDPDRFDIGRSPNRHIGFGGGIHFCL 
 
CYP260B1      GAPLARMEARVGVSLLLERFPALRADPTVQ-PTFSTAPRGAAAFGPDQIPALLV------ 
CYP264B1      GVFLARVQARIVLEELLRRCHRIVLRT--DRLEWQAAL---NTRSPVALPIEVIPVSTTA 
CYP267B1      GAMLARIEAAIAFSTLLRRLPRIELATSTRDIVWSEWP---TIRGPAAVPVVF------- 
 
CYP260B1      ----------- ->24% identity 
CYP264B1      ARESPVVQGIW  
CYP267B1      -----------  ->33% identity 
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4.1.2 Screening of terpenes and terpenoids 
Table 3: Screening of terpenes and terpenoids by selected P450s from So ce56. Conversions are marked with 
– (no conversion), + (<10%), ++ (<50%), +++ (> 50%) and n.d. (not determined). 
substrate CYP 
109C1 
CYP 
109C2 
CYP 
109D1 
CYP 
260A1 
CYP 
260B1 
CYP 
264A1 
CYP 
264B1 
CYP 
267A1 
CYP 
267B1 
τ-muurolol - - - + - + - + ++ 
β-phellandrene - - - - - - - ++ ++ 
nootkatone n.d. n.d. -* +++ +++* -* +++ +++ +++ 
          
* Tested by Michael Ringle 
In vitro reactions were performed as shown before (see 2.3). The temperature profile for the 
measurements was adjusted for these substances; the starting temperature was 50°C and then 
the temperature was ramped to 300°C with a rate of 10°C/min. 
 
4.1.3 Screening of aromatic compounds 
Table 4: Screening of aromatic compounds by selected P450s from So ce56. Conversions are marked with – 
(no conversion), + (<10%), ++ (<50%), +++ (> 50%) and n.d. (not determined). 
substrate CYP109C1 CYP109C2 CYP109D1 CYP260A1 CYP260B1 CYP264A1 CYP264B1 
4-allylanisole - - - - - - - 
eugenol - - - - - - - 
4-ethylphenol - - - - - - - 
4-picoline - - - - - - - 
cinnamyl 
alcohol 
n.d. n.d. n.d. n.d. - n.d. n.d. 
cinnamaldehyde Traces of 
product 
Traces of 
product 
+ Traces of 
product 
+++ Traces of 
product 
Traces of 
product 
cinnamic acid n.d. n.d. n.d. n.d. - n.d. n.d. 
 
In vitro reactions were performed as shown before (see 2.3) with small modifications. After 
extraction, the solvent was removed to a total volume of about 40 µl and then analyzed by GC-
MS. The temperature profile for the measurements was also adjusted for these substances; the 
starting temperature was 40°C and then the temperature was ramped to 170°C with a rate of 
10°C/min. 
Cinnamaldehyde and derivatives were solely analyzed by HPLC-DAD. The whole-cell conversion 
of cinnamaldehyde by CYP260B1 as well as extraction and purification of the product was done 
as described previously (see 2.3). The product was characterized by NMR spectroscopy and 
identified as cinnamic acid (see Figure 9). 
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Figure 9: Structure of cinnamic acid. 
NMR data: 
1H NMR (CDCl3): 7.62 (d, J=16.0 Hz, H3), 7.40-7.00 (Ar-H, 5x), 6.29 (d, J= 16.0, H2); 
13C NMR 
(CDCl3): 172.06 (C1), 147.00 (C3), 130.72 (Ar), 128.94 (Ar, 2x), 128.25 (Ar, 2x), 126.45 (Ar), 117.29 
(C2). 
 
4.1.4 Screening of drugs 
In addition to the published data (see 2.4), some drugs were additionally screened with 
CYP109C1, CYP109C2, CYP109D1, CYP260A1, CYP260B1, CYP264A1 and CYP264B1. 
Table 5: Screening of drugs with selected myxobacterial P450s. Conversions are marked with – (no 
conversion) or the value for the total conversion in [%]. 
substrate CYP109C1 CYP109C2 CYP109D1 CYP260A1 CYP260B1 CYP264A1 CYP264B1 
amodiaquine - - - - - - - 
papaverine - - - Traces of 
product 
- - - 
diclofenac - - - Traces of 
product 
- Traces of 
product 
Traces of 
product 
diltiazem - - - Traces of 
product 
- - - 
haloperidol - - - ~5% Traces of 
product 
- - 
losartan - - - - - - - 
piroxicam - - - - - - - 
quinine - - - ~30% (2 
products) 
- - - 
repaglinide - - - - - Traces of 
product 
- 
ritonavir - - - - - Traces of 
product 
- 
tamoxifen - - - - - - - 
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4.2 Abbreviations 
 
AdR Adrenodoxin reductase 
Adx Adrenodoxin 
°C Degree Celcius 
CYP Cytochrome P450 
δ Chemical shift [ppm] 
CPR Cytochrome P450 reductase 
Da Dalton 
DAD Diode array detector 
DMSO Dimethyl sulfoxide 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetate 
FAD Flavine adenine dinucleotide 
FDA Food and drug administration 
FMN Flavine mononucleotide 
g Gram 
GC Gas chromatogaphy 
GPP Geranyl pyrophosphate 
h Hour 
HPLC High performance liquid chromatography 
Hz Hertz 
J Coupling constant 
l Liter 
M Molar 
m Meter 
MS Mass spectrometry 
min Minute 
n.d. Not determined 
NADPH Nicotinamide adenine dinucleotide phosphate 
NMR Nuclear magnetic resonance spectroscopy 
NRPS Nonribosomal polypeptide synthase 
ORF Open reading frame 
P450 Cytochrome P450 
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PKS Polyketide synthase 
ppm Parts per million 
rpm Rounds per minute 
s Second 
SRS Substrate recognition site 
T Temperature 
UV/Vis Ultraviolet–visible spectroscopy 
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Abbreviations for amino acids 
A Alanine M Methionine 
C Cysteine N Asparagine 
D Aspartate P Proline 
E Glutamate Q Glutamine 
F Phenylalanine R Arginine 
G Glycine S Serine 
H Histidine T Threonine 
I Ispleucine V Valine 
K Lysine W Tryptophan 
L Leucine Y Tyrosine 
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